Lamotrigine: Nursing Drug Guide, SJS/TEN Rash Risk & NCLEX Review
Lamotrigine treats epilepsy and maintains bipolar I disorder, but nursing safety centers on any new skin or mucosal lesion during titration—most life-threatening rashes appear within 2–8 weeks, especially with valproate co-therapy or dose escalation faster than labeling allows. You cannot tell benign from Stevens-Johnson syndrome early; hold and escalate at the first sign.
Life-threatening rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have occurred with lamotrigine. Risk is higher in pediatric patients, with valproate, when initial dose or escalation exceeds labeling, and in some patients with HLA-B*1502. Discontinue at the first sign of rash unless clearly not drug-related—benign rashes cannot be distinguished reliably from serious reactions.
📋 Contents
⚡ Quick facts
Most common brand names
Lamotrigine is the generic name on most orders.
Common brands: Lamictal (tablet, chewable dispersible tablet for oral suspension, ODT), Lamictal XR (extended-release). Starter kits and ODT titration kits align with recommended first 5 weeks of dosing. Verify formulation—immediate-release, ODT, chewable dispersible, and XR are not interchangeable without prescriber and pharmacy approval.
Why we give it — Indications
Lamotrigine is an anticonvulsant used for seizure disorders and bipolar maintenance—not for acute manic or depressive episodes as monotherapy.
| Use | Nursing relevance |
|---|---|
| Epilepsy — adjunctive therapy | Partial-onset, primary generalized tonic-clonic, and generalized seizures of Lennox-Gastaut syndrome in patients aged 2 years and older |
| Epilepsy — monotherapy conversion | Adults ≥16 years converting from single AEDs including carbamazepine, phenytoin, phenobarbital, primidone, or valproate |
| Bipolar I disorder — maintenance | Delays mood episodes after acute episodes are stabilized with standard therapy; target maintenance often 200 mg/day (100 mg/day with valproate; up to 400 mg/day with enzyme inducers) |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The full mechanism in humans is not completely established. Labeling states lamotrigine may inhibit voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating release of excitatory amino acids such as glutamate and aspartate. A therapeutic plasma concentration range has not been established—dosing is based on clinical response.
Dosing overview
Dosing depends on indication, age, weight, and concomitant medications. To reduce rash risk, do not exceed recommended initial doses or escalation rates. Use product-specific tables in current labeling (Tables 1–6 for Lamictal).
Lamictal Starter Kits and ODT Patient Titration Kits supply labeled doses for the first 5 weeks based on concomitant drugs. Using them reduces dosing errors that drive serious rash.
Before you give it — Safety check
Pretreatment checks
- Confirm indication (seizure disorder vs bipolar maintenance) and exact product (IR, ODT, chewable, XR)
- Complete medication reconciliation for valproate, enzyme-inducing AEDs, estrogen-containing contraceptives, and rifampin
- Verify titration schedule matches concomitant drugs—never accept a “standard” 25 mg daily start if valproate is present
- Review rash history and prior hypersensitivity to lamotrigine or ingredients
- Discuss HLA-B*1502 context with prescriber for patients of Han Chinese, Thai, or other at-risk ancestry when institution screens
- Baseline skin assessment and patient teach-back on rash reporting
Contraindications (DailyMed)
- Hypersensitivity to lamotrigine or ingredients (e.g., prior rash, angioedema, mucosal ulceration)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Valproate (valproic acid, divalproex) | More than doubles lamotrigine levels; increases serious rash risk | Use valproate-specific titration; hold if rash; do not escalate faster than Table 1 or 5 |
| Carbamazepine, phenytoin, phenobarbital, primidone | Decrease lamotrigine concentrations ~40% | Higher maintenance doses may be needed; seizure breakthrough if levels fall—notify team |
| Estrogen-containing oral contraceptives | Decrease lamotrigine ~50%; pill-free week may transiently raise levels | Maintenance dose may need up to 2-fold increase while on OCP; taper when stopping OCP per prescriber |
| Rifampin, lopinavir/ritonavir, atazanavir/ritonavir | Alter lamotrigine clearance | Follow labeling tables for inducers; coordinate with pharmacy |
| Organic cation transporter 2 substrates (narrow index) | Not recommended concomitant use per labeling | Flag new orders to pharmacist before administration |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet, orally disintegrating tablet (ODT), chewable dispersible tablet for suspension, or extended-release tablet per order.
- Follow medication administration rights; confirm MAR dose against titration schedule, not prior shift habit
- ODT: place on tongue to disintegrate; swallow with or without liquid
- Chewable dispersible tablets: may be swallowed whole, chewed, or dispersed in liquid per product instructions
- XR tablets: swallow whole—do not crush or chew unless product labeling permits
- Document exact strength given; lamotrigine is a frequent look-alike/confusion drug with other AEDs
Unless a life-threatening reaction requires immediate discontinuation (e.g., suspected SJS/TEN), taper over at least 2 weeks (~50% reduction per week) to avoid increased seizure frequency or status epilepticus per labeling.
Expected therapeutic response
- Reduced seizure frequency or intensity when used for epilepsy
- Longer interval between mood episodes in bipolar I maintenance therapy
- Patient tolerates titration without rash, severe dizziness, or ataxia limiting function
- No signs of aseptic meningitis, DRESS, or HLH during early therapy
Red flags — Stop and act
Hold lamotrigine and obtain urgent prescriber/pharmacist direction when any of the following appear:
- Any new maculopapular rash, target lesions, blistering, or mucosal erosions (mouth, eyes, genitals)
- Fever with rash, lymphadenopathy, or facial swelling suggesting DRESS/multiorgan hypersensitivity
- Severe headache with fever, neck stiffness, photophobia, or nausea/vomiting—possible aseptic meningitis
- Fever with hepatosplenomegaly, cytopenias, or neurologic changes—consider hemophagocytic lymphohistiocytosis (HLH)
- Syncope, palpitations, or new arrhythmia symptoms (labeling warns of cardiac conduction effects)
- New suicidal ideation or behavioral changes per antiepileptic drug class warning
Adverse effects
| Adverse effect | Clinical context | Nursing response |
|---|---|---|
| SJS / TEN / rash-related death | Boxed warning; most within 2–8 weeks; can occur later | Stop at first rash sign; emergency dermatology; do not rechallenge if SJS/TEN suspected |
| DRESS / multiorgan hypersensitivity | Fever, rash, lymphadenopathy, hepatitis, renal or hematologic involvement | Stop drug; urgent evaluation; do not restart if alternate cause not found |
| HLH | May present 8–24 days after start with fever, rash, cytopenias, high ferritin | Stop lamotrigine if HLH suspected; ICU/hematology pathway |
| Aseptic meningitis | Headache, fever, nuchal rigidity; rapid return if rechallenged | Stop drug; evaluate for other meningitis causes; avoid rechallenge |
| Dizziness, ataxia, diplopia, somnolence | Common in epilepsy trials (≥10% adults) | Fall precautions; avoid driving until stable; review dose and interactions |
| Suicidal thoughts or behavior | Class warning for antiepileptic drugs | Screen mood; escalate behavioral changes per policy |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdoses up to 15 g have been reported, some fatal. Manifestations include ataxia, nystagmus, seizures (including tonic-clonic), decreased consciousness, coma, and intraventricular conduction delay.
Labeling guidance
- No specific antidotes for lamotrigine overdose
- Hospitalize; supportive care with frequent vital signs and close observation
- Induce emesis when indicated with airway protection; immediate-release product is rapidly absorbed
- Hemodialysis removes only about 20% over 4 hours in renal failure patients—effectiveness uncertain
- Contact local poison control / medical toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Lamotrigine vs levETIRAcetam vs LACosamide — use tall-man lettering and independent double-check on AED orders
- Immediate-release vs XR vs ODT vs chewable — different pharmacokinetics; wrong formulation can alter levels and rash risk during titration
- Starter kit vs maintenance bottle — verify week of therapy matches kit color/schedule
- Valproate co-therapy titration — standard epilepsy start (25 mg daily) is an overdose scenario when valproate is on the MAR
- Similar tablet strengths — 25, 100, 150, 200 mg tablets; use barcode scanning and pharmacy verification
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| First 8 weeks | Daily full skin and mucosal check; most serious rashes occur early |
| Valproate on MAR | Confirm 25 mg every other day (not daily) for initial bipolar/epilepsy weeks unless orders document otherwise |
| Oral contraceptive changes | Starting or stopping estrogen products may require maintenance dose change—flag pharmacy before next dose |
| Meningitis mimic | New headache + fever on lamotrigine is not “just side effects” until evaluated |
| Teaching moment | Patients must report rash or mouth sores before the next dose—even if mild or pink |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pediatric patients | Higher incidence of serious rash than adults; weight-based dosing; whole tablets only for chewable suspension strengths |
| Valproate co-therapy | Increased serious rash risk in adults and children; slower titration mandatory |
| HLA-B*1502–positive patients | Increased SJS/TEN risk in some Asian ancestries; genotyping does not replace rash vigilance |
| Prior rash to other AEDs | Increased nonserious and possibly serious rash risk |
| Hepatic impairment | Reduce initial, escalation, and maintenance doses ~25% (moderate/severe) or ~50% (severe with ascites) |
| Renal impairment | Reduced maintenance doses may be effective; use caution—limited data in severe renal impairment |
| Pregnancy | Animal data suggest fetal harm; human registry data do not show major malformation rates clearly above baseline; oral cleft signal in one registry—specialist counseling; do not abruptly stop for epilepsy without prescriber plan |
| Lactation | Present in breast milk; infant apnea, drowsiness, poor sucking, rash reported—monitor infant; reduce maternal dose postpartum if pregnancy dose was increased |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Skin, oral mucosa, and conjunctiva daily during titration and early maintenance; patient-reported rash before each dose
- Seizure frequency, mood stability, and breakthrough symptoms when used for epilepsy or bipolar maintenance
- Neurologic status: ataxia, diplopia, somnolence, severe headache, neck stiffness
- Complete blood count and liver function tests when DRESS, HLH, or hepatitis suspected
- Mood and suicidal ideation per antiepileptic drug class warning
- Cardiac symptoms if patient has underlying conduction disease (per labeling)
- Not specified in the reviewed prescribing information for routine therapeutic drug level monitoring in all patients—levels may be ordered per prescriber when interactions change
Document
- Rash description (distribution, mucosa, fever, days since lamotrigine start or last dose increase)
- Hold actions and prescriber/pharmacist notifications with time
- Concomitant valproate, enzyme inducers, and contraceptive changes
- Patient teach-back: “call before next dose if any rash or mouth sore”
Patient teaching
- Report any rash, mouth sores, fever, or blistering immediately—do not take the next dose until you speak with the care team unless directed
- Serious rashes can start as mild pink spots—you cannot tell safe from dangerous at home
- Take exactly the prescribed titration dose; do not increase early because you “feel fine”
- Report severe headache with fever, stiff neck, or vomiting—possible medication-related meningitis
- Do not stop seizure medicine suddenly unless the prescriber orders an emergency stop—sudden stop can cause seizures
- Tell clinicians about all medicines, including birth control—doses may need adjustment when contraceptives start or stop
- Report depression, suicidal thoughts, or unusual mood changes promptly
- Carry medical identification listing antiepileptic therapy if prescribed for seizures
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Any new rash or suspected drug-related skin reaction (unless prescriber documents clearly not drug-related)
- Fever with rash, lymphadenopathy, facial swelling, or organ dysfunction concern (DRESS/HLH)
- Severe headache with fever, neck stiffness, or photophobia (aseptic meningitis concern)
- Scheduled dose exceeds labeling titration for concomitant valproate or enzyme inducers until pharmacy verifies
- Patient discontinued lamotrigine for rash previously—do not restart without explicit risk–benefit orders
- Syncope or new serious arrhythmia symptoms pending cardiac evaluation
Hold parameters can vary by institution. Follow prescriber orders, pharmacy guidance, and local policy.
Clinical practice integration and workflow
Lamotrigine harm most often follows rash blindness (treating a new rash as minor) or titration errors with valproate. Build a first-8-week surveillance habit on every pass.
1. Check-before-you-give protocol
- Inspect skin, oral mucosa, and conjunctiva
- Ask: “Any new rash, mouth sores, or fever since your last dose?”
- Match MAR dose to valproate/enzyme-inducer titration table for current week
- Confirm formulation (IR, ODT, XR) matches order
2. High-alert and safety badge
SJS/TEN risk — stop at first rash signBoxed-warning dermatologic reactions place lamotrigine in a zero-tolerance rash surveillance category even when not on institutional high-alert lists.
3. Clinical workflow: hold and question rules
- If rash appears during titration, hold and escalate same shift—do not administer the scheduled dose “while waiting for callback”
- If MAR shows daily lamotrigine with valproate during weeks 1–2, hold and verify with pharmacy before giving
- If contraceptive starts or stops, notify prescriber/pharmacist before next maintenance dose
4. Critical teach-back questions
- “What skin changes mean you should call us before your next dose?” (Any new rash, blistering, mouth sores, or fever with rash.)
- “Can you increase your dose early if you feel well?” (No—escalation must follow prescriber schedule to prevent serious rash.)
5. Care coordination
Pharmacist: Titration kit verification, valproate/OCP interaction dosing, formulation substitution checks
Neurology / psychiatry: Seizure or mood plan if drug stopped; alternative therapy; gradual withdrawal orders
🧠 Quick mental checklist
- New rash, mouth ulcer, or eye redness today?
- MAR matches valproate-specific titration for this week?
- Headache + fever + stiff neck on a new patient?
- Contraceptive started, stopped, or pill-free week—dose still correct?
- Patient can name the one symptom that means “hold and call”?
Lamotrigine NCLEX practice questions
Use this NCLEX-style clinical judgment practice block with a tabbed case panel (MAR, labs, history, nursing notes), then priority action, SATA cue recognition, titration trend interpretation, matrix urgency judgment, hold documentation, and overdose cloze—focused on SJS/TEN rash risk and valproate titration errors.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Lamotrigine 50 mg PO daily (started 11 days ago; increased from 25 mg daily 3 days ago)
- Divalproex 500 mg PO BID (ongoing 4 months)
- Combined oral contraceptive daily
- Acetaminophen 650 mg PO q6h PRN headache
- Baseline (prestart): WBC 6.9 K/uL, AST 22 U/L, ALT 19 U/L
- Today: WBC 7.1 K/uL, AST 24 U/L, ALT 21 U/L
- Valproate level 78 mcg/mL (therapeutic per prescriber note)
- Lamotrigine level: not drawn
- 24-year-old with bipolar I disorder on valproate maintenance; lamotrigine added for mood stabilization
- No prior medication rash; no known HLA-B*1502 testing
- Reports adherence to contraceptive; denies alcohol or illicit drugs
- Last mood episode 5 months ago; currently euthymic
- Patient reports itchy red spots on trunk and one painful mouth ulcer since this morning
- Temp 37.4 °C; denies neck stiffness; mild headache
- States spots are “probably stress” and asks to keep tonight’s lamotrigine dose
- 0900 lamotrigine dose already given; 2100 dose due
Answer key & rationale
Frequently asked questions
When should a nurse hold lamotrigine for a rash?
Discontinue at the first sign of rash unless clearly not drug-related. Nurses should hold the dose and escalate the same shift when any new rash appears during titration.
Why is titration slower with valproate?
Valproate inhibits glucuronidation and more than doubles lamotrigine levels. Exceeding recommended starting doses or escalation rates increases serious rash risk.
Is there an antidote for lamotrigine overdose?
No specific antidotes are listed. Care is supportive with hospitalization and close monitoring. Contact local poison control per protocol.
How do oral contraceptives affect lamotrigine?
Estrogen-containing contraceptives decrease lamotrigine concentrations about 50%. Maintenance doses may need significant adjustment when contraceptives start or stop.
Can patients breastfeed on lamotrigine?
Lamotrigine is in breast milk. LactMed supports breastfeeding for many patients with infant monitoring for rash, sedation, apnea, and poor feeding.
What is the aseptic meningitis warning?
Headache, fever, nausea, vomiting, and neck stiffness may occur within days to six weeks. Symptoms often resolve after stopping the drug; rechallenge can recur rapidly and severely.
References
- U.S. National Library of Medicine. LAMICTAL (lamotrigine) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678
- Drugs and Lactation Database (LactMed). Lamotrigine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501268/
- U.S. Food and Drug Administration. Suicidal thoughts and behavior in patients taking antiepileptic drugs.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidal-thoughts-and-behavior-antiepileptic-drugs
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.